	Neoadjuvant chemoradiation
Pathologic complete response
Paclitaxel
Esophageal cancer
Tumor regression grade
	phase II trial
treatment
neoadjuvant treatment
radiotherapy
neoadjuvant chemoradiation
postoperative complications
tumor
survival
patients
surgery
Transhiatal esophageal resection
complete pathologic response
esophageal cancer
resection rates
pathologic complete tumor regression rate
Stage II
weeks
Survival time
complete response rates
mortality
response
regimen
study
due
significant
chemoradiation
trials
Cancer
RCT
time

